2017 (3rd) International Symposium on Innovative Medicine Research & Development and Translational Strategy was successfully held by Sichuan PriMed Bio-tech Group Co., Ltd., and Chengdu PriMed HuaYing Bio-tech Co., Ltd. in Chengdu on Sep. 25th, 2017. It was supported by Science & Technology Department of Sichuan Province, Sichuan Food & Drug Administration, Chengdu Medical Health Industry Promotion Office,The Management Committee of Chengdu Hi-tech Industrial Development Zone. It was sponsored by Merck Sharp & Dohme Corp, The Management Committee of Chengdu Tianfu International Bio-Industry Town, Sichuan Provincial People’s Hospital, West China hospital, and Hinova Pharmaceutical Inc.
The launching ceremony of “Chronic Disease Database Consortium” was held at the start of the conference, there are 12 consortium members including hospitals, research centers and big pharma all over the world, such as PriMed Bio-tech, West China hospital, Southern Medical University, Chinese Academy of Science,Tianjin TASLY Pharmaceutical Co., Ltd and so on. The purposes of the consortium is that the integration analysis of large database of primate chronic disease can help us to analyze and explore the nature of life's phenomena, and focuses on clinical transformation studies of cardiovascular disease, non-alcoholic fatty liver disease, liver fibrosis, eye diseases and neurological diseases could promote the original breakthrough in life sciences.
This symposium focuses on the latest development of disease model on non-alcoholic fatty liver disease and liver fibrosis, diabetic complications, heart failure ,cognitive disorder and imaging technology in the diagnosis of hepatic fibrosis and other disease.
21 experts and researchers from international research institutes and labs including Merck Sharp & Dohme Corp, Brown University, Abbott,Chinese Academy of Sciences, West China Hospital of Sichuan University, and Fourth Military Medical University delivered keynote speeches concerning non-human primate models ,new drug development and new diagnostic techniques.
Dr. Jeffrey L. Evelhoch , who was vice president of Merck Sharp & Dohme Corp, mentioned in the interview : “It’s a combination of unique population of non-human primates that you have and the group of people very committed, very highly-trained and educated in skill who are part of PriMed. I think we are after a great start right, I think there is lot of potential, we are now in the point where the teams want actually to put studies here, and start using what you have developed and keep building and get to move things further and further long, and I see the potential for a lot of drug studies been done. ”
Tel : +86-28-85921823
Fax : +86-28-62491302
Zip code : 610041